Maria M Berikopoulou, Argyro Konstantopoulou, Sotirios Argyrakis, Maria Theochari, Panagiota Drosatou, Anna Messaritaki, Dimitra Dimopoulou
{"title":"Ηidradenitis suppurativa associated with autoimmunity in children and adolescents; a case-based review.","authors":"Maria M Berikopoulou, Argyro Konstantopoulou, Sotirios Argyrakis, Maria Theochari, Panagiota Drosatou, Anna Messaritaki, Dimitra Dimopoulou","doi":"10.1007/s00296-025-05828-0","DOIUrl":null,"url":null,"abstract":"<p><p>Hidradenitis suppurativa (HS) is an uncommon chronic inflammatory disease in children, characterized by painful abscesses and lesions. It has been associated with various autoimmune conditions, including inflammatory bowel diseases (IBDs) and rheumatologic disorders. We present a 13-year-old female with Hurley stage III HS, who developed macrophage activation syndrome (MAS). Clinical presentation and laboratory findings led to a diagnosis of systemic lupus erythematosus (SLE). Treatment with immunosuppressive therapy resulted in symptom resolution and clinical improvement. In addition, a case-based review was conducted to evaluate the patterns, clinical features and possible underlying mechanisms in the pediatric patients with HS and autoimmune diseases. Twenty pediatric cases were included with a median HS onset age of 15 years (IQR: 4 years). Among these, 55% were diagnosed with IBDs, followed by autoimmune arthritis and psoriasis (10% each). Treatment was individualized, with 95% receiving biologic agent and 55% receiving antimicrobials. This case and case-based review of literature highlight the potential overlap between HS and autoimmunity, especially SLE, in the pediatric population and emphasize the importance of proactive monitoring for coexisting autoimmune diseases in patients with HS, in order to facilitate early detection and effective management.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"45 4","pages":"83"},"PeriodicalIF":3.2000,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rheumatology International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00296-025-05828-0","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Hidradenitis suppurativa (HS) is an uncommon chronic inflammatory disease in children, characterized by painful abscesses and lesions. It has been associated with various autoimmune conditions, including inflammatory bowel diseases (IBDs) and rheumatologic disorders. We present a 13-year-old female with Hurley stage III HS, who developed macrophage activation syndrome (MAS). Clinical presentation and laboratory findings led to a diagnosis of systemic lupus erythematosus (SLE). Treatment with immunosuppressive therapy resulted in symptom resolution and clinical improvement. In addition, a case-based review was conducted to evaluate the patterns, clinical features and possible underlying mechanisms in the pediatric patients with HS and autoimmune diseases. Twenty pediatric cases were included with a median HS onset age of 15 years (IQR: 4 years). Among these, 55% were diagnosed with IBDs, followed by autoimmune arthritis and psoriasis (10% each). Treatment was individualized, with 95% receiving biologic agent and 55% receiving antimicrobials. This case and case-based review of literature highlight the potential overlap between HS and autoimmunity, especially SLE, in the pediatric population and emphasize the importance of proactive monitoring for coexisting autoimmune diseases in patients with HS, in order to facilitate early detection and effective management.
期刊介绍:
RHEUMATOLOGY INTERNATIONAL is an independent journal reflecting world-wide progress in the research, diagnosis and treatment of the various rheumatic diseases. It is designed to serve researchers and clinicians in the field of rheumatology.
RHEUMATOLOGY INTERNATIONAL will cover all modern trends in clinical research as well as in the management of rheumatic diseases. Special emphasis will be given to public health issues related to rheumatic diseases, applying rheumatology research to clinical practice, epidemiology of rheumatic diseases, diagnostic tests for rheumatic diseases, patient reported outcomes (PROs) in rheumatology and evidence on education of rheumatology. Contributions to these topics will appear in the form of original publications, short communications, editorials, and reviews. "Letters to the editor" will be welcome as an enhancement to discussion. Basic science research, including in vitro or animal studies, is discouraged to submit, as we will only review studies on humans with an epidemological or clinical perspective. Case reports without a proper review of the literatura (Case-based Reviews) will not be published. Every effort will be made to ensure speed of publication while maintaining a high standard of contents and production.
Manuscripts submitted for publication must contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in an appropriate version of the 1964 Declaration of Helsinki. It should also be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted.